Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
() -- Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday. The investment firm revised its price targets for several biopharma stocks it covers ah